XML 53 R22.htm IDEA: XBRL DOCUMENT
v3.25.3

TAXES ON INCOME | 12 Months Ended
--- | ---
Jul. 31, 2025
Income Tax Disclosure [Abstract] |
TAXES ON INCOME | NOTE 11: TAXES ON INCOME a. Components of income taxes excluding cumulative effects of changes in accounting principles, other comprehensive income, and equity in net results of affiliated companies accounted for after-tax for the years ended July 31 were as follows: b. The Company recorded loss before taxes on income as follows: SCHEDULE OF LOSS BEFORE TAXES ON INCOME
|  | 2025 |  |  | 2024 |
|  | Year ended July 31, |
|  | 2025 |  |  | 2024 |
Domestic |  | $ | (23,999,920 | ) |  | $ | 23,946,952 | )
Foreign |  |  | (2,556,220 | ) |  |  | (28,878,500 | )
Loss before taxes on income |  | $ | (26,556,140 | ) |  | $ | (4,931,548 | )
BriaCell Therapeutics Corp Notes to the Consolidated Financial Statements For the Years Ended July 31, 2025 and 2024 (Expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 11: TAXES ON INCOME (Cont.) c. The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 27% (2024 - 27%) to the effective tax rate is as follows: SCHEDULE OF EFFECTIVE INCOME TAX
|  | 2025 |  |  | 2024 |
|  | Year ended July 31, |
|  | 2025 |  |  | 2024 |
Net loss before recovery of income taxes |  | $ | (26,556,140 | ) |  | $ | (4,931,548 | )
Expected income tax (recovery) expense |  |  | (7,170,160 | ) |  |  | (1,331,518 | )
Tax rate changes and effect of taxes of subsidiaries at foreign rates |  |  | 1,448,710 |  |  |  | 1,467,021 |
Share-based compensation and other non-deductible expenses |  |  | 240,070 |  |  |  | 1,697,204 |
Share issuance cost booked directly to equity |  |  | (375,750 | ) |  |  | - |
Adjustments in respect of prior periods |  |  | 868,490 |  |  |  | - |
R&D Credits |  |  | (1,284,010 | ) |  |  | (3,903,153 | )
Effect of spin-out transaction |  |  | - |  |  |  | (297,781 | )
Valuation allowance |  |  | 6,272,650 |  |  |  | 2,368,228 |
Income tax (recovery) |  | $ | - |  |  | $ | - |
d. The Company had no income tax expense for the years ended July 31, 2025, and 2024, due to its history of operating losses and valuation allowances. e. Significant components of the Company’s deferred tax assets are as follows: SCHEDULE OF DEFERRED TAX ASSETS NET
|  | 2025 |  |  | 2024 |
|  | July 31, |
|  | 2025 |  |  | 2024 |
Deferred Tax Assets: |  |  |  |  |  |  |  |
Property and equipment |  | $ | 730 |  |  |  | 731 |
Marketable Securities |  |  | 11,760 |  |  |  | 15,678 |
Intellectual property |  |  | 260,860 |  |  |  | 256,741 |
Warrant liability |  |  | - |  |  |  | - |
Share issuance costs |  |  | 310,230 |  |  |  | 376,978 |
Investment in BC Therapeutics |  |  | 44,650 |  |  |  | 19,172 |
Operating tax losses carried forward |  |  | 5,067,840 |  |  |  | 4,850,799 |
Operating tax losses carried forward- USA |  |  | 8,494,300 |  |  |  | 5,545,125 |
Research and Development |  |  | 14,240,640 |  |  |  | 10,879,373 |
Total deferred tax assets |  |  | 28,431,010 |  |  |  | 21,944,597 |
Valuation allowance |  |  | (24,329,720 | ) |  |  | (18,034,710 | )
Net deferred tax assets |  | $ | 4,101,290 |  |  | $ | 3,909,887 |
Deferred Tax Liability: |  |  |  |  |  |  |  |
Intellectual Property |  | $ | - |  |  | $ | - |
Warrant liability |  |  | (4,053,520 | ) |  |  | (3,848,762 | )
Property, plant, and equipment |  |  | (47,770 | ) |  |  | (61,125 |
Total net deferred tax liabilities |  |  | (4,101,290 | ) |  |  | (3,909,887 | )
Valuation allowance |  |  | - |  |  |  | - |
Net deferred tax assets (liabilities) |  | $ | - |  |  | $ | - |
| f. | The Company has net deferred tax assets relating primarily to net operating loss (“NOL”) carryforwards, research and development, and share issuance costs. Subject to certain limitations, the Company may use these deferred tax assets to offset taxable income in future periods. Due to the Company’s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the Company’s deferred tax assets, as it is more likely than not that such assets will not be realized. The net change in the total valuation allowance for the year ended July 31, 2025, was $1,792,500.
BriaCell Therapeutics Corp Notes to the Consolidated Financial Statements For the Years Ended July 31, 2025 and 2024 (Expressed in US Dollars, except share and per share data and unless otherwise indicated) NOTE 11: TAXES ON INCOME (Cont.) At July 31, 2025, the Company had US federal NOL carryforwards of approximately $40,450,000. The federal net operating losses have expiry periods ranging between 2033 and indefinitely. The Company also has Canadian net operating loss carryovers of approximately $18,770,000 as of July 31, 2025. The Canadian net operating losses have expiry periods ranging between 2035 and 2045. The Company has adopted the provisions of ASC 740-10, which clarifies the accounting for uncertain tax positions. ASC 740-10 requires that the Company recognize the impact of a tax position in its financial statements if the position is more likely than not to be sustained upon examination based on the technical merits of the position. For the year ended July 31, 2025, the Company had no material unrecognized tax benefits, and based on the information currently available, no significant changes in unrecognized tax benefits are expected in the next 12 months. The Company’s policy is to recognize interest and penalties related to uncertain tax positions as income tax expense. The Company has no accruals for interest or penalties on its accompanying consolidated balance sheets as of July 31, 2025, and 2024, and has not recognized interest or penalties in the consolidated statements of operations for the years ended July 31, 2025, and 2024.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration